Opinion|Videos|November 5, 2024
Confirming Eligibility for Lutetium Therapy
Author(s)Oliver Sartor, MD
Key Takeaways
- 68Gallium PSMA-11 PET is preferred for confirming lutetium therapy eligibility due to its high specificity in detecting PSMA expression.
- Alternatives include 18F-DCFPyL PET, which also targets PSMA, offering a viable option when 68Gallium PSMA-11 PET is unavailable.
Oliver Sartor, MD, discusses how 68gallium PSMA-11 PET is indeed the preferred imaging modality for confirming eligibility for lutetium therapy, but when unavailable, alternative options such as F-18 PSMA PET, conventional bone scintigraphy, or CT/MRI may be considered, albeit with potential limitations in sensitivity and specificity.
Advertisement
Is this the imaging modality of choice to use to confirm eligibility for lutetium therapy? What other options are available use 68gallium PSMA-11 PET is not available?
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: September 2026
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
5